Pharmaceutical Valuation Multiples
Explore private market Pharmaceutical valuation multiples with benchmarks structured by stage and region. Updated quarterly.
Pharmaceutical
Pharmaceutical companies discover, develop, and commercialise small molecule drugs and biologics that address unmet medical needs. Private market valuations are primarily pipeline-driven — reflecting clinical stage progression, probability of approval, peak sales potential, and competitive differentiation of therapeutic candidates.
The category spans specialty pharma, rare disease, oncology, CNS, and cardiometabolic programs. DealMatrix tracks valuation dynamics across 7 funding stages and all major global regions, updated every quarter.
Sector
Pharmaceutical
Health & Life Sciences
Sector tracked since
2000
25+ years of data
EV/SALES & EV/EBITDA ACROSS
6 Regions · 7 Stages
Modelled independently via proprietary econometric approach
UPDATE FREQUENCY
Quarterly
Data updates & model improvement
Pharmaceutical Valuation Multiples
Select a region and funding stage to preview how Pharmaceutical companies are valued in private markets. Full data available on the platform.
The Venionaire DealMatrix Multiples Model
DealMatrix multiples are derived through a five-step model combining public capital market comparables, proprietary VC/PE/M&A transaction data, and macroeconomic indicators.
The model produces three components: The reported public multiple, the model-predicted multiple, and the lower bound predicted multiple averaged into the DealMatrix Composite, then adjusted for region and funding stage. The methodology follows the IPEV Guidelines 2025.
Adcendo Series C: $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
raised
Valuation
Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
raised
Valuation
Latent Labs secures €47.9 million in funding to realise the potential of AI-powered, programmable biology
raised
Valuation
Quibim Announces $50 Million in Series A Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers
raised
Valuation
Brenus Pharma Raises $25 Million to Accelerate Clinical Trials of Its Precision Cancer Vaccines.
raised
Valuation
Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’
raised
Valuation
Health & Life Sciences
Pharmaceutical
Health & Life Sciences
MedTech
